Thrombolysis in Factor Xa-inhibitors Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT06878066

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Guri Hagberg (from the registry)
Registry
  • NCT NCT06878066
  • EU CT 2023-509907-34-01
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, Norway, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06878066. Randomized; single masking; primary purpose treatment. Start 2025-03-14 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Thrombolysis in Factor Xa-inhibitors Trial
Acronym
SIFT
Condition
Stroke
Condition
Stroke (in Patients With Atrial Fibrillation)
Condition
Acute Ischemic Stroke
Condition
Anticoagulant Therapy
Condition
Factor Xa Inhibitor
Condition
Intracranial Hemorrhages
Condition
Hemorrhagic Transformation Due to Acute Stroke
Condition
Bleeding in the Brain
Intervention (Drug)
thrombolysis therapy
Lead sponsor
Guri Hagberg (class: other)
Collaborator
Klinbeforsk (class: other)
Collaborator
Clinical Trial Unit (CTU), Oslo University Hospital (class: not stated)

Record details

Record id
cardio:ct-nct06878066
Content hash
3247b8f6d46320992fbf5a348e462f23ede081ad00fd7f3caf1656ef49dbd89f